vs

Side-by-side financial comparison of CORE MOLDING TECHNOLOGIES INC (CMT) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.

CORE MOLDING TECHNOLOGIES INC is the larger business by last-quarter revenue ($74.7M vs $62.1M, roughly 1.2× Cytek Biosciences, Inc.). On growth, CORE MOLDING TECHNOLOGIES INC posted the faster year-over-year revenue change (19.5% vs 8.1%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-2.9M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -2.2%).

Core Molding Technologies, Inc. was founded in 1988 and now based in Columbus, Ohio. The company manufactures sheet molding compounds (SMC), and molds fiberglass reinforced plastics. It occupies over 1,000,000 square feet of manufacturing space and its main subsidiaries are in Matamoros, Mexico, Gaffney, South Carolina, and Cincinnati, Ohio. In 2011, Core Molding Technologies formed Core Specialty Composites, LLC.

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

CMT vs CTKB — Head-to-Head

Bigger by revenue
CMT
CMT
1.2× larger
CMT
$74.7M
$62.1M
CTKB
Growing faster (revenue YoY)
CMT
CMT
+11.4% gap
CMT
19.5%
8.1%
CTKB
More free cash flow
CTKB
CTKB
$1.2M more FCF
CTKB
$-1.8M
$-2.9M
CMT
Faster 2-yr revenue CAGR
CTKB
CTKB
Annualised
CTKB
17.7%
-2.2%
CMT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CMT
CMT
CTKB
CTKB
Revenue
$74.7M
$62.1M
Net Profit
$-44.1M
Gross Margin
15.2%
52.9%
Operating Margin
4.8%
-9.0%
Net Margin
-70.9%
Revenue YoY
19.5%
8.1%
Net Profit YoY
-557.1%
EPS (diluted)
$0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMT
CMT
CTKB
CTKB
Q4 25
$74.7M
$62.1M
Q3 25
$58.4M
$52.3M
Q2 25
$79.2M
$45.6M
Q1 25
$61.4M
$41.5M
Q4 24
$62.5M
$57.5M
Q3 24
$73.0M
$51.5M
Q2 24
$88.7M
$46.6M
Q1 24
$78.1M
$44.9M
Net Profit
CMT
CMT
CTKB
CTKB
Q4 25
$-44.1M
Q3 25
$1.9M
$-5.5M
Q2 25
$4.1M
$-5.6M
Q1 25
$2.2M
$-11.4M
Q4 24
$9.6M
Q3 24
$3.2M
$941.0K
Q2 24
$6.4M
$-10.4M
Q1 24
$3.8M
$-6.2M
Gross Margin
CMT
CMT
CTKB
CTKB
Q4 25
15.2%
52.9%
Q3 25
17.4%
52.7%
Q2 25
18.1%
52.3%
Q1 25
19.2%
48.6%
Q4 24
15.8%
58.5%
Q3 24
16.9%
56.3%
Q2 24
20.0%
54.6%
Q1 24
17.0%
51.3%
Operating Margin
CMT
CMT
CTKB
CTKB
Q4 25
4.8%
-9.0%
Q3 25
4.4%
-17.6%
Q2 25
6.6%
-23.3%
Q1 25
4.6%
-36.1%
Q4 24
1.4%
5.2%
Q3 24
4.9%
-8.2%
Q2 24
8.4%
-18.3%
Q1 24
6.1%
-23.9%
Net Margin
CMT
CMT
CTKB
CTKB
Q4 25
-70.9%
Q3 25
3.2%
-10.5%
Q2 25
5.1%
-12.2%
Q1 25
3.6%
-27.5%
Q4 24
16.8%
Q3 24
4.3%
1.8%
Q2 24
7.2%
-22.4%
Q1 24
4.8%
-13.8%
EPS (diluted)
CMT
CMT
CTKB
CTKB
Q4 25
$0.35
Q3 25
$0.22
Q2 25
$0.47
Q1 25
$0.25
Q4 24
$-0.01
Q3 24
$0.36
Q2 24
$0.73
Q1 24
$0.43

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMT
CMT
CTKB
CTKB
Cash + ST InvestmentsLiquidity on hand
$38.1M
$90.9M
Total DebtLower is stronger
$17.6M
Stockholders' EquityBook value
$158.2M
$341.7M
Total Assets
$228.1M
$461.5M
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMT
CMT
CTKB
CTKB
Q4 25
$38.1M
$90.9M
Q3 25
$42.4M
$93.3M
Q2 25
$43.2M
$75.5M
Q1 25
$44.5M
$95.3M
Q4 24
$41.8M
$98.7M
Q3 24
$42.3M
$162.3M
Q2 24
$37.8M
$177.9M
Q1 24
$26.6M
$168.8M
Total Debt
CMT
CMT
CTKB
CTKB
Q4 25
$17.6M
Q3 25
$18.2M
Q2 25
$18.8M
Q1 25
$19.2M
Q4 24
$19.7M
Q3 24
$20.2M
Q2 24
$20.6M
Q1 24
$21.1M
Stockholders' Equity
CMT
CMT
CTKB
CTKB
Q4 25
$158.2M
$341.7M
Q3 25
$155.4M
$378.6M
Q2 25
$153.5M
$377.6M
Q1 25
$149.9M
$379.6M
Q4 24
$147.4M
$395.7M
Q3 24
$147.8M
$385.5M
Q2 24
$147.5M
$389.1M
Q1 24
$142.8M
$392.6M
Total Assets
CMT
CMT
CTKB
CTKB
Q4 25
$228.1M
$461.5M
Q3 25
$219.7M
$494.9M
Q2 25
$219.9M
$493.3M
Q1 25
$223.6M
$482.6M
Q4 24
$209.6M
$499.5M
Q3 24
$220.7M
$491.2M
Q2 24
$225.7M
$483.7M
Q1 24
$212.3M
$492.1M
Debt / Equity
CMT
CMT
CTKB
CTKB
Q4 25
0.11×
Q3 25
0.12×
Q2 25
0.12×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.14×
Q2 24
0.14×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMT
CMT
CTKB
CTKB
Operating Cash FlowLast quarter
$5.0M
$-771.0K
Free Cash FlowOCF − Capex
$-2.9M
$-1.8M
FCF MarginFCF / Revenue
-3.9%
-2.9%
Capex IntensityCapex / Revenue
10.7%
1.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.9M
$-8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMT
CMT
CTKB
CTKB
Q4 25
$5.0M
$-771.0K
Q3 25
$4.6M
$-3.9M
Q2 25
$3.5M
$108.0K
Q1 25
$6.1M
$-125.0K
Q4 24
$5.0M
$2.0M
Q3 24
$9.2M
$13.2M
Q2 24
$15.9M
$6.2M
Q1 24
$5.1M
$4.0M
Free Cash Flow
CMT
CMT
CTKB
CTKB
Q4 25
$-2.9M
$-1.8M
Q3 25
$-346.0K
$-4.6M
Q2 25
$880.0K
$-1.5M
Q1 25
$4.3M
$-974.0K
Q4 24
$509.0K
$1.1M
Q3 24
$7.0M
$12.2M
Q2 24
$13.0M
$5.2M
Q1 24
$3.2M
$3.4M
FCF Margin
CMT
CMT
CTKB
CTKB
Q4 25
-3.9%
-2.9%
Q3 25
-0.6%
-8.7%
Q2 25
1.1%
-3.2%
Q1 25
7.0%
-2.3%
Q4 24
0.8%
1.9%
Q3 24
9.6%
23.7%
Q2 24
14.6%
11.0%
Q1 24
4.1%
7.6%
Capex Intensity
CMT
CMT
CTKB
CTKB
Q4 25
10.7%
1.6%
Q3 25
8.4%
1.3%
Q2 25
3.3%
3.5%
Q1 25
2.9%
2.0%
Q4 24
7.2%
1.6%
Q3 24
3.1%
2.0%
Q2 24
3.3%
2.3%
Q1 24
2.4%
1.3%
Cash Conversion
CMT
CMT
CTKB
CTKB
Q4 25
Q3 25
2.44×
Q2 25
0.86×
Q1 25
2.79×
Q4 24
0.21×
Q3 24
2.92×
14.05×
Q2 24
2.47×
Q1 24
1.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CMT
CMT

Segment breakdown not available.

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

Related Comparisons